| Tysabri (natalizumab) / Biogen, Royalty |
2007-007394-22: The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning |
|
|
| Ongoing | 4 | 10 | Europe | Tysabri, Tysabri, Tysabri | Imperial College London | Multiple Sclerosis | | | | |
| Ongoing | 4 | 60 | Europe | beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada | Turku University Hospital, Novartis Pharma | Multiple sclerosis MS-tauti | | | | |
2016-000345-31: Reduce the number of natalizumab infusions in patients with multiple sclerosis Verminderen van het aantal giften van natalizumab bij patiënten met multiple sclerose |
|
|
| Ongoing | 4 | 60 | Europe | natalizumab, Solution for infusion, tysabri | VU medical center, de Hersenstichting | multiple sclerosis multiple sclerose, MS MS, Diseases [C] - Nervous System Diseases [C10] | | | | |
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros. |
|
|
| Ongoing | 4 | 150 | Europe | Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio | Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet | Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10] | | | | |
2013-002433-38: Essai visant à tester la différence d’efficacité du Natalizumab, versus le fingolimod, 2 médicaments pour le traitement de la sclérose en plaques |
|
|
| Not yet recruiting | 4 | 500 | Europe | natalizumab, fingolimod, Concentrate for solution for infusion, Capsule, TYSABRI, GILENYA | CHU de Toulouse, FP7 Health Innovation-1 | Sclérose en plaques, Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-002566-13: Personalizing the treatment with natalizumab in patients with multiple sclerosis |
|
|
| Not yet recruiting | 4 | 300 | Europe | natalizumab, Solution for infusion, Tysabri | Amsterdam University Medical Center, Innovatiefonds Zorgverzekeraars, Stichting MS Research, de Hersenstichting | Relapsing remitting multiple sclerosis, Multiple sclerosis (MS), Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04048577: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab |
|
|
| Recruiting | 4 | 10 | US | Dosing Interruption of Natalizumab, Dosing Interruption of Tysabri | Berkovich, Regina MD, PhD Inc., Biogen, Cedars-Sinai Medical Center | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 11/21 | 12/21 | | |
| Completed | 4 | 30 | US | Natalizumab | State University of New York at Buffalo | Multiple Sclerosis | 12/23 | 12/23 | | |
NCT05532163: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) |
|
|
| Terminated | 4 | 1 | Europe | Natalizumab, Tysabri, BG00002 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 10/23 | 10/23 | | |
| Recruiting | 4 | 56 | Europe | Methylprednisolone, Placebo, natalizumab (NTZ), fingolimob (FTY) | University Hospital, Clermont-Ferrand | Multiple Sclerosis | 06/24 | 07/24 | | |
NCT04178005: Cladribine Tablets After Treatment With Natalizumab (CLADRINA) |
|
|
| Active, not recruiting | 4 | 40 | US | Cladribine, Mavenclad | University of Texas Southwestern Medical Center, EMD Serono | Multiple Sclerosis | 08/24 | 12/26 | | |
| Terminated | 4 | 1 | US | Natalizumab 300 MG in 15 ML Injection | Vanderbilt University Medical Center, Biogen | Multiple Sclerosis | 04/23 | 04/23 | | |
SUPERNEXT, NCT04225312: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis |
|
|
| Enrolling by invitation | 4 | 300 | Europe | Personalized extended interval dosing of natalizumab, EID, Standard interval dosing, SID | Amsterdam UMC, location VUmc, Stichting MS Research, Innovatiefonds Zorgverzekeraars, Stichting Treatmeds | Relapsing Remitting Multiple Sclerosis | 03/25 | 03/25 | | |
| Active, not recruiting | 4 | 800 | Europe, US | Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod) | The Cleveland Clinic, University of Nottingham | Multiple Sclerosis, Relapsing-Remitting | 07/27 | 09/30 | | |
ACTRN12605000769684: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation |
|
|
| Not yet recruiting | 3/4 | 900 | | | Biogen Idec, Biogen Idec, Elan Pharmaceuticals | Multiple Sclerosis | | | | |
